Quote:IgG4-related disease (IgG4-RD) is a newly classified, immunological condition. It involves potentially multi-organ inflammation and fibrosis, characterized (in most cases) by elevated serum IgG4 levels and presenting as tissue edema with fibrosis and marked inflammatory infiltration of IgG4-positive plasma cells. IgG4-RD constitutes a number of conditions previously classified separately according to the organ affected, therefore, it occurs in various forms: autoimmune pancreatitis type 1 (AIP1), Mikulicz’s disease (MD), dacryoadenitis, sclerosing cholangitis, lymphadenopathy, and – less commonly – retroperitoneal fibrosis, Riedel’s thyroiditis, sclerosing sialadenitis (Kuttner’s tumor), and interstitial lung or kidney disease.

Quote:By now, you have probably heard about the Science Immunology paper showing that people who have received mRNA Covid vaccines produce more of an unusual antibody called IgG4 over time. A number of mRNA skeptics, including me, wrote about it last week.


But the reasons why the paper is so troubling may still not be clear. So here’s a (with luck) digestible explanation, starting with what is probably the most important question: what’s the worst-case scenario?

1: What’s the worst-case scenario?

Glad you asked.

The worst-case scenario: the mRNA shots lead to a doom loop, robbing vaccinated people of a crucial immune system tool against the coronavirus in a way that worsens with each new infection.

Thus, over time, the average severity of Covid infections will increase. People will take longer to get better once they’re infected. Hospitalizations and deaths will rise. The health-care system will come under worsening strain.

Oh, and some people may suffer nasty autoimmune side effects too, including pancreatitis, kidney disease, and even aneurysms.

Quote:Shortly after the initial two mRNA vaccine doses, the IgG response mainly consists of the pro-inflammatory subclasses IgG1 and IgG3.


Here, we report that several months after the second vaccination, SARS-CoV-2-specific antibodies were increasingly composed of non-inflammatory IgG4, which were further boosted by a third mRNA vaccination and/or SARS-CoV-2 variant breakthrough infections. IgG4 antibodies among all spike-specific IgG antibodies rose on average from 0.04% shortly after the second vaccination to 19.27% late after the third vaccination.

This induction of IgG4 antibodies was not observed after homologous or heterologous SARS-CoV-2 vaccination with adenoviral vectors.


We found an mRNA vaccine-driven expansion of memory B cells expressing IgG4. We detected spike-specific IgG4 antibodies in about half of the serum samples collected five to seven months after the second immunization, all of which did not show any IgG4 at earlier time points. For all other IgG subclasses, a decline was seen in the same period. Moreover, after the third immunization, IgG4 levels sharply increased and became detectable in almost all vaccinees.

In summary, our study demonstrates an mRNA vaccine-induced antiviral IgG4 antibody response appearing late after secondary immunization. Further investigations are needed to clarify the precise immunological mechanisms driving this response and to evaluate whether an IgG4-driven antibody response affects subsequent viral infections and booster vaccinations. This is not only relevant for potential future vaccine campaigns against SARS-CoV-2, but also for new mRNA-based vaccine developments against other pathogens.

Quote:In summary, we characterized the comprehensive effects of extended immunization with RBD booster vaccines in a balb/c mouse model. Our findings revealed that repeated dosing after the establishment of vaccine response might not further improve the antigen-specific reactivity; instead, it could cause systematic tolerance and inability to generate effective humoral and cellular immune responses to current SARS-CoV-2 variants. Our study provides timely information for the prevention of COVID-19. It puts an extended immunization course with two or more RBD-based vaccine boosters at debate, and warns for the future applications of vaccine enhancers without proper evaluation of serum antibody titers and T cell functions.

Quote:An item of note is the above sentence, “It is possible that the mRNA may be integrated or re-transcribed in some cells”. The so-called reverse transcription, that is, vaccine mRNA becoming part of the human DNA genome in some affected cells, was originally dismissed without evidence by the so-called ‘Covid science’, until it was demonstrated in in-vitro experiment

To be sure that their finding is not spurious, they included a control group of people who never received the Covid vaccines.

Quote:

The study group, from southern Italy, was 40 subjects, 20 were vaccinated with the full cycle of mRNA vaccine as of April 2022, being part of the health sector, and 20 were unvaccinated with negativity for COVID-19 to nasopharyngeal test and with no titre of any antibodies. Other 20 unvaccinated persons were added that were positive for COVID-19.

The three groups were looked at.

It turns out that [i]only the people in the vaccinated subgroup were found to carry vaccine-derived spike protein[/i]. What is worse, vaccine spike protein was found as late as six months after the last dose.

Quote:

The specific PP-Spike fragment was found in 50% of the biological sample analysed. This presence was independent of the SARS-CoV-2 IgG antibody titre. The antibody titres had a geometric mean of 629.86BAU/mL. The minimum time PP-Spike was detected was 69 days after vaccination, while the maximum time was 187 days. All controls (samples from unvaccinated individuals) were negative. The control group (20 unvaccinated people) was also tested after contracting COVID-19 and was negative for PP-spike.

Nowhere does the study state that spike protein production ends after 187 days – the upper limit on time after vaccination was an artefact of the study design.